Published in J Virol on September 09, 2009
Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev (2011) 2.22
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol (2010) 1.50
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood (2015) 1.44
Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection. J Virol (2012) 1.14
CTCF and Rad21 act as host cell restriction factors for Kaposi's sarcoma-associated herpesvirus (KSHV) lytic replication by modulating viral gene transcription. PLoS Pathog (2014) 0.91
Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase and histone variant H2AX. Virology (2011) 0.90
Dynamic association of gammaherpesvirus DNA with core histone during de novo lytic infection of primary cells. Virology (2011) 0.88
An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection. PLoS Pathog (2012) 0.88
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
In vivo function of the murid herpesvirus-4 ribonucleotide reductase small subunit. J Gen Virol (2011) 0.81
Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits. Invest Ophthalmol Vis Sci (2010) 0.81
Cell-based screening assay for antiviral compounds targeting the ability of herpesvirus posttranscriptional regulatory proteins to stabilize viral mRNAs. J Virol (2013) 0.80
Target DNA detection and quantitation on a single cell with single base resolution. Technology (Singap World Sci) (2013) 0.80
De novo infection of B cells during murine gammaherpesvirus 68 latency. J Virol (2011) 0.78
Acyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent Individuals. PLoS One (2015) 0.77
Epstein-Barr virus infection. N Engl J Med (2000) 5.93
A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell (1995) 3.17
Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol (1980) 2.69
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis (2005) 2.09
Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer (1989) 1.97
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 1.94
Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med (1982) 1.90
B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood (2005) 1.52
Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother (2003) 1.47
Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol (1999) 1.39
On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood (2007) 1.36
Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses. Am J Med (1982) 1.25
Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation (1997) 1.19
Size and stability of the Epstein-Barr virus major internal repeat (IR-1) in Burkitt's lymphoma and lymphoblastoid cell lines. Virology (1989) 1.16
Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet (1983) 1.16
Long-term shedding of infectious epstein-barr virus after infectious mononucleosis. J Infect Dis (2005) 1.15
Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. J Clin Microbiol (1995) 1.10
Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients. Transplantation (1990) 1.09
Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation (1998) 1.05
Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis (2005) 1.04
The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia. Virology (2007) 0.95
Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. J Infect Dis (2008) 0.81
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis (2013) 4.92
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis (2008) 3.52
Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature (2011) 2.82
Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med (2006) 2.81
Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 2.77
Treatment trials for post-Lyme disease symptoms revisited. Am J Med (2013) 2.75
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15
Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 2.12
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol (2005) 2.08
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science (2013) 2.00
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A (2008) 1.95
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol (2003) 1.92
IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood (2004) 1.82
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A (2008) 1.77
Conformational motion of the ABC transporter MsbA induced by ATP hydrolysis. PLoS Biol (2007) 1.76
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol (2006) 1.69
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol (2005) 1.68
Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet (2002) 1.67
catena-Poly[[bis-(nitrato-κO)copper(II)]-bis-[μ-1,4-bis-(pyridin-3-ylmeth-oxy)benzene-κN:N']]. Acta Crystallogr Sect E Struct Rep Online (2011) 1.61
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail (2003) 1.60
Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer. PLoS One (2010) 1.56
Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma (2007) 1.54
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol (2011) 1.51
Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell (2006) 1.51
Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res (2004) 1.50
Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases. Arch Dermatol (2006) 1.49
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol (2011) 1.46
Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin Vaccine Immunol (2009) 1.46
Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis (2012) 1.45
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect (2004) 1.42
ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. Ann Appl Stat (2008) 1.41
Tropical dermatology: viral tropical diseases. J Am Acad Dermatol (2003) 1.40
MD/PhDs are more likely than MDs to choose a career in academic dermatology. Dermatol Online J (2008) 1.39
An HIV-Positive Male with a Herald Plaque. Clin Infect Dis (2011) 1.38
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
Metachronous Merkel cell carcinoma on both cheeks. Acta Derm Venereol (2012) 1.37
Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods (2004) 1.37
Tropical dermatology: Venomous arthropods and human skin: Part I. Insecta. J Am Acad Dermatol (2012) 1.35
Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett (2006) 1.34
Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31
Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One (2012) 1.31
Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol (2007) 1.30
G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion (2003) 1.29
Molecular ecology of pyrethroid knockdown resistance in Culex pipiens pallens mosquitoes. PLoS One (2010) 1.27
Neural correlates of a clinical continuous performance test. Magn Reson Imaging (2008) 1.27
Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease. Clin Vaccine Immunol (2010) 1.25
Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol (2013) 1.25
The expanding spectrum of eschar-associated rickettsioses in the United States. Arch Dermatol (2010) 1.24
Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol (2008) 1.24
Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol (2008) 1.24
Intermolecular associations determine the dynamics of the circadian KaiABC oscillator. Proc Natl Acad Sci U S A (2010) 1.24
Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (2011) 1.24
Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology (2008) 1.23
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol (2007) 1.22
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. J Virol (2009) 1.21
Cluster without fluster: The effect of correlated outcomes on inference in randomized clinical trials. Stat Med (2008) 1.21
Cutaneous metastasis to the chest wall from prostate cancer. Int J Dermatol (2006) 1.20
Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J Virol (2007) 1.18
Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther (2007) 1.17
Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis (2011) 1.17
Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J Virol (2002) 1.17
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis (2009) 1.17
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
Dermatology residency program characteristics that correlate with graduates selecting an academic dermatology career. Arch Dermatol (2006) 1.14
Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood (2003) 1.14
Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant (2004) 1.14
Detection of vaccinia virus DNA, but not infectious virus, in the blood of smallpox vaccine recipients. Vaccine (2007) 1.12
Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine (2005) 1.09
The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination. Jpn J Infect Dis (2010) 1.09